Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling
- PMID: 19782692
- DOI: 10.1016/j.jtbi.2009.09.021
Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling
Abstract
The RANK-RANKL-OPG system is an essential signaling pathway involved in bone cell-cell communication, with ample evidence that modification of the RANK-RANKL-OPG signaling pathway has major effects on bone remodeling. The first focus of this paper is to demonstrate that a theoretical model of bone cell-cell interactions is capable of qualitatively reproducing changes in bone associated with RANK-RANKL-OPG signaling. To do this we consider either biological experiments or bone diseases related to receptor and/or ligand deficiencies, including RANKL over-expression, ablation of OPG production and/or RANK receptor modifications. The second focus is to investigate a wide range of possible therapeutic strategies for re-establishing bone homeostasis for various pathologies of the RANK-RANKL-OPG pathway. These simulations indicate that bone diseases associated with the RANK-RANKL-OPG pathway are very effective in triggering bone resorption compared to bone formation. These results align with Hofbauer's "convergence hypothesis", which states that catabolic bone diseases most effectively act through the RANK-RANKL-OPG system. Additionally, we demonstrate that severity of catabolic bone diseases strongly depends on how many components of this pathway are affected. Using optimization algorithms and the theoretical model, we identify a variety of successful "virtual therapies" for different disease states using both single and dual therapies.
Similar articles
-
[The OPG/RANKL/RANK system and bone resorptive disease].Sheng Wu Gong Cheng Xue Bao. 2003 Nov;19(6):655-60. Sheng Wu Gong Cheng Xue Bao. 2003. PMID: 15971575 Review. Chinese.
-
The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.Expert Rev Cardiovasc Ther. 2006 Nov;4(6):801-11. doi: 10.1586/14779072.4.6.801. Expert Rev Cardiovasc Ther. 2006. PMID: 17173497 Review.
-
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.Cytokine Growth Factor Rev. 2004 Dec;15(6):457-75. doi: 10.1016/j.cytogfr.2004.06.004. Cytokine Growth Factor Rev. 2004. PMID: 15561602 Review.
-
RANK/RANKL: regulators of immune responses and bone physiology.Ann N Y Acad Sci. 2008 Nov;1143:123-50. doi: 10.1196/annals.1443.016. Ann N Y Acad Sci. 2008. PMID: 19076348 Review.
-
The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.J Endocrinol Invest. 2009;32(4 Suppl):6-9. J Endocrinol Invest. 2009. PMID: 19724159 Review.
Cited by
-
Possible antiosteoporotic mechanism of Cicer arietinum extract in ovariectomized rats.Int J Clin Exp Pathol. 2015 Apr 1;8(4):3477-90. eCollection 2015. Int J Clin Exp Pathol. 2015. PMID: 26097532 Free PMC article.
-
Bone balance within a cortical BMU: local controls of bone resorption and formation.PLoS One. 2012;7(7):e40268. doi: 10.1371/journal.pone.0040268. Epub 2012 Jul 23. PLoS One. 2012. PMID: 22844401 Free PMC article.
-
Computational modeling of interactions between multiple myeloma and the bone microenvironment.PLoS One. 2011;6(11):e27494. doi: 10.1371/journal.pone.0027494. Epub 2011 Nov 8. PLoS One. 2011. PMID: 22110661 Free PMC article.
-
HIF-1α disturbs osteoblasts and osteoclasts coupling in bone remodeling by up-regulating OPG expression.In Vitro Cell Dev Biol Anim. 2015 Sep;51(8):808-14. doi: 10.1007/s11626-015-9895-x. Epub 2015 Apr 10. In Vitro Cell Dev Biol Anim. 2015. PMID: 25859979
-
Antiosteoporosis Effects, Pharmacokinetics, and Drug Delivery Systems of Icaritin: Advances and Prospects.Pharmaceuticals (Basel). 2022 Mar 24;15(4):397. doi: 10.3390/ph15040397. Pharmaceuticals (Basel). 2022. PMID: 35455393 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
